Pharmaceutical combinations of an angiotensin receptor antagonist and a nep inhibitor

NO20151656A1Inactive Publication Date: 2007-09-10NOVARTIS PHARMA AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NO20151656
Authority / Receiving Office
NO · NO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2006-11-08
Filing Date
2015-12-03
Publication Date
2007-09-10
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing hypertension treatments, particularly for essential hypertension, often require combination therapies with different mechanisms of action but can have adverse side effects and are not always effective in controlling blood pressure and cardiovascular diseases.

Method used

A dual-acting compound comprising an angiotensin receptor antagonist (valsartan) and a neutral endopeptidase inhibitor (NEPi) forms a supramolecular complex through non-covalent bonds, such as hydrogen bonding and ionic interactions, creating a unique molecular entity that combines both mechanisms of action.

Benefits of technology

The dual-acting compound effectively lowers blood pressure and enhances plasma levels of natriuretic peptides, providing a therapeutic benefit for hypertension and cardiovascular diseases with reduced side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A specific combination, bound pro-drug or a compound of an angiotensin receptor antagonist and a NEP inhibitor is used in the treatment of hypertension
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to dual-acting compounds, in particular a dual-acting molecule in which the angiotensin receptor blocker and the neutral endopeptidase inhibitor are linked via non-covalent bonding, or supramolecular complexes of angiotensin receptor blockers and neutral endopeptidase inhibitors, also described as bound pro-drugs, such as mixed salts or co-crystals, as well as pharmaceutical combinations containing such a dual-acting compound, methods for preparing such dual-acting compounds and methods for treating a subject with such a dual-acting compound. Specifically, the present invention relates to a dual-acting compound or supramolecular complex of two active agents having the same or different modes of action in one molecule.

[0002] Angiotensin II is a hormone that causes blood vessels to constrict. This in turn can result in high blood pressure and strain on the heart. It is known that angiotensin II interacts with specific receptors on the surface of target cells. Two receptor subtypes for angiotensin II, namely AT1 and AT2, have been identified so far. Recently, great efforts have been made to identify substances that bind to the ATI receptor. Angiotensin receptor blockers (ARBs, angiotensin II antagonists) are known to prevent angiotensin II from binding to its receptors in the walls of blood vessels, thereby resulting in lower blood pressure. Due to the binding to the ATI receptor, such antagonists may therefore be useful as anti-hypertensive agents or for the treatment of congestive heart failure, among other indications.

[0003] Neutral endopeptidase (EC 3.4.24.11; enkephalinase; atriopeptidase; NEP) is a zinc-containing metalloprotease that cleaves a number of peptide substrates at the amino side of the hydrophobic residues [see Pharmacol Rev, Vol. 45, p. 87 (1993)]. Substrates for this enzyme include, but are not limited to, atrial natriuretic peptide (ANP, also known as ANF), brain natriuretic peptide (BNP), met- and leu-enkephalin, bradykinin, neurokinin A, endothelin-1, and substance P. ANP is a potent vasorelaxant and natriuretic agent [seeJ Hypertens, Vol. 19, p. 1923 (2001)]. Infusion of ANP in normal subjects resulted in a reproducible, marked increase in natriuresis and diuresis, which included increases in fractional sodium excretion, urine flow rate, and glomerular filtration rate [see J Clin Pharmacol, Vol. 27, p. 927 (1987)].However, ANP has a short half-life in circulation, and NEP in renal cortical membranes has been shown to be the major enzyme responsible for the degradation of this peptide [see Peptides, Vol. 9, p. 173 (1988)]. Thus, inhibitors of NEP (neutral endopeptidase inhibitors, NEPi) should increase plasma levels of ANP and thus be expected to induce natriuretic and diuretic effects.

[0004] While agents such as angiotensin receptor blockers and neutral endopeptidase inhibitors may be useful in controlling hypertension, essential hypertension is a polygenic disease and is not always adequately controlled with monotherapy. Approximately 333 million adults in developing countries and approximately 65 million Americans (1 in 3 adults) had high blood pressure in 2000 [see Lancet, Vol. 365, p. 217 (2005); and Hypertension, Vol. 44, p. 398 (2004)]. Prolonged and uncontrolled hypertensive vascular disease ultimately leads to a number of pathological changes in target organs, such as the heart and kidney. Persistent hypertension can lead to as well as increase the incidence of stroke. Therefore, there is a strong need to evaluate the effectiveness of antihypertensive therapy, an investigation of additional cardiovascular methods, beyond those related to blood pressure reduction, to further understand the benefits of combined treatment.

[0005] The manifestation of hypertensive vascular diseases is multifactorial. In some circumstances, drugs with different mechanisms of action have been combined. However, simply considering combinations of drugs with different modes of action does not necessarily lead to combinations with beneficial effects. Consequently, there is a need for effective combination therapy that does not have adverse side effects.

[0006] The present invention relates to a dual-acting compound, such as a supramolecular complex comprising: (a) an angiotensin receptor antagonist; (b) a neutral endopeptidase inhibitor (NEPi); and (c) a pharmaceutically acceptable cation,

[0007] wherein, in a first aspect of the invention, the dual-acting compound is a compound comprising the NEP inhibitor (2Z?,4»S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, and the angiotensin receptor antagonist valsartan, and has the formula [((5)-N-valeryl-N-{[2,-(1 / -tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine) ((2i?,4*S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester)]Nai-3 • x H2O, wherein x is 0 to 3.

[0008] The angiotensin receptor antagonist and NEPi have acidic groups that facilitate formation of the dual-acting compound, such as the supramolecular complex of the invention. In the invention, the angiotensin receptor antagonist is valsartan and NEPi is

[0009] (2,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, (also known as N-(3-carboxy-1-oxopropyl)-(4,5)-[7-phenylphenylmethyl]-4-amino-2,2-methylmenanonic acid ethyl ester). Preferably, the dual-acting compound, especially the supramolecular complex, is a mixed salt or a co-crystal.

[0010] In a second aspect, the present invention relates to a pharmaceutical composition comprising (a) the aforementioned dual-acting compound; and (b) at least one pharmaceutically acceptable additive.

[0011] In a third aspect, the present invention relates to the dual-acting compound according to claim 1 for the preparation of a medicament for use in a method of treating or preventing a disease or condition, such as hypertension, heart failure (acute and chronic), congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic heart myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial fibrillation, harmful vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, other vascular disorders, such as migraine,peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke.,

[0012] Figure 1 shows a pictorial representation of the unit cell of the supramolecular complex of trisodium [3-((15',3i?)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3 '-methyl-2' -(pentanoyl {2'' -(tetrazol-5-ylate)biphenyl-4' -ylmethyl}amino)butyrate] hemipentahydrate which includes two asymmetric units. The following color code is used: gray = carbon atom; blue = nitrogen atom; red = oxygen atom; violet = sodium atom.

[0013] The present invention relates to a dual-acting compound, in particular a supramolecular complex, in particular a supramolecular complex of two active agents with different mechanisms of action, namely an angiotensin receptor antagonist and a neutral endopeptidase inhibitor, which can form a unique molecular component for the treatment of patients with various cardiovascular and / or renal diseases.

[0014] The two active agents are combined with each other to form a single dual-acting compound, in particular a supramolecular complex. In doing so, a new molecular or supramolecular entity is formed which has distinct properties different from the above-mentioned physical combination.

[0015] Thus, the present invention relates to a compound comprising the NEP inhibitor (2?,4?)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, and the angiotensin receptor antagonist valsartan, and having the formula [((*S)-jN-valeryl-jN-{[2'-(1'-tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine) ((2?,4?)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester)]Nai-3 • x H2O, wherein x is 0 to 3.

[0016] In the context of the present invention, the term "dual-acting compound" is intended to describe that these compounds have two different modes of action in one compound, one being angiotensin receptor blockade as a result of the ARB molecular component of the compound and the other being neutral endopeptidase inhibition as a result of the NEPi molecular component of the compound.

[0017] In the context of the present invention, the term "compound" is intended to describe a chemical substance that includes covalent bonds in the two pharmaceutically active agents, the ARB and / or NEPi molecular components and non-covalent interactions between these two pharmaceutically active agents, the ARB and NEPi molecular components. Typically, hydrogen bonding can be observed between the two pharmaceutically active agents, the ARB and NEPi molecular components. Ionic bonds may be present between the cation and one or both of the two pharmaceutically active agents, the ARB and NEPi molecular components. Other types of bonds may also be present in the compound such as van der Waals forces. For illustrative purposes, the dual-acting compound of the invention can be presented as follows:

[0018] wherein L is a linking moiety, such as a cation or is a non-covalent bond and m is an integer from 1 or more. In other words, the ARB and NEPi moiety may be linked via non-covalent bonds such as hydrogen bonds. Alternatively or additionally, they may be linked via a linking moiety such as a cation.

[0019] In one embodiment, the dual-acting compound can be considered to be a bound pro-drug, whereby the binding moiety, such as the cation, that binds the two pharmaceutically active agents, ARB and NEPi, forms the pro-drug of these agents which is released as the bound pro-drug is ingested and absorbed.

[0020] In a preferred embodiment, the dual-acting compound is a complex, particularly a supramolecular complex.

[0021] In the context of the present invention, the term "supramolecular complex" is intended to describe an interaction between the two pharmaceutically active agents, the cations and any other component present such as a solvent, in particular water, by means of non-covalent, intermolecular bonds between them. This interaction leads to an association of the components present in the supramolecular complex which distinguishes this complex from a physical mixture of the components.

[0022] The non-covalent intermolecular bond may be any interaction known in the literature to form such supramolecular complexes, such as hydrogen bonding, van der Waals forces and 7r-7i stacking. Ionic bonds may also be present. Preferably, ionic bonding and additional hydrogen bonding exist to form a network of interactions in the complex. The supramolecular complex preferably exists in the solid state, but may also be present in liquid media. As a preferred embodiment of the invention, the complex is crystalline and in this case it is preferably a mixed crystal or co-crystal.

[0023] Typically, the dual-acting compound, especially the supramolecular complex, exhibits properties such as melting point, IR spectrum, etc. that are different from a physical mixture of the components.

[0024] Preferably, the dual-acting compound, in particular the supramolecular complex, has a network of non-covalent bonds, in particular hydrogen bonds, between the two pharmaceutically active agents and any solvent, if present, preferably water. Furthermore, it is preferred that the dual-acting compound, in particular the supramolecular complex, has a network of non-covalent bonds, in particular ionic and hydrogen bonds, between the two pharmaceutically active agents, the cation and any solvent, if present, preferably water. The cation is preferably coordinated to several oxygen ligands, thus providing a bond between these oxygen ligands. The oxygen ligands come from the carbonyl and carboxylate groups present in the two pharmaceutically active agents and preferably also from any solvent, if present, preferably water.

[0025] The dual-acting compound comprises a molecular moiety of an angiotensin receptor antagonist. This means that a molecular moiety derived from an angiotensin receptor antagonist participates in the structure of the dual-acting compound. The angiotensin receptor antagonist is a part of the compound and is linked to the NEP inhibitor directly or indirectly via non-covalent bonds. For convenience, in the present invention, the term "angiotensin receptor antagonist" will be used when describing this part of the compound. The angiotensin receptor antagonist (ARB) used according to the invention is valsartan.

[0026] ARBs for use in preparing the complex of the invention may be obtained from commercial sources or may be prepared according to known methods. ARBs may be used in the context of the present invention in their free form, as well as in any suitable salt or ester form.

[0027] Preferred salt forms include acid addition salts. The compounds having at least one acidic group (e.g. COOH or 5-tetrazolyl) can also form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, e.g. sodium, potassium, calcium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, e.g. ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine, or a mono-, di- or trihydroxy lower alkylamine, e.g. mono-, di- or tri-ethanolamine. Corresponding internal salts can further be formed. Salts which are unsuitable for pharmaceutical applications, but which can be used, for example, for the isolation or purification of the free compounds I or their pharmaceutically acceptable salts, are also included.Even more preferred salts are, for example, selected from the mono-sodium salt in amorphous form; the di-sodium salt of valsartan in amorphous or crystalline form, especially in hydrate form, thereof.

[0028] Mono-potassium salt of valsartan in amorphous form; dipotassium salt of valsartan in amorphous or crystalline form, especially in hydrate form, thereof.

[0029] Calcium salt of valsartan in crystalline form, especially in hydrate form, primarily the tetrahydrate thereof; magnesium salt of valsartan in crystalline form, especially in hydrate form, primarily the hexahydrate thereof; calcium / magnesium mixed salt of valsartan in crystalline form, especially in hydrate form; éw-diethylammonium salt of valsartan in crystalline form, especially in hydrate form; éw-dipropylammonium salt of valsartan in crystalline form, especially in hydrate form; éw-dibutylammonium salt of valsartan in crystalline form, especially in hydrate form, primarily the hemihydrate thereof; mono-L-arginine salt of valsartan in amorphous form; bis-L-arginine salt of valsartan in amorphous form; mono-L-lysine salt of valsartan in amorphous form; bis-L-lysine salt of valsartan in amorphous form.

[0030] Preferably, in preparing the dual-acting compound, particularly the complex of the present invention, the free form of ARB is used.

[0031] The angiotensin receptor blocker used in the combination or complex according to the invention is Valsartan, the molecular structure of which is shown below

[0032]

[0033] Valsartan can exist in racemic form or as one of the two isomers shown below

[0034] Valsartan ((5)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine) used in the invention may be obtained from commercial sources or may be prepared according to known methods. For example, the preparation of valsartan is described in U.S. Patent No. 5,399,578 and EP 0 443 983, the entire disclosures of which are incorporated herein by reference. Valsartan may be used in the context of the present invention in its free acid form, as well as in any suitable salt form. In addition, esters or other derivatives of the carboxylic group may be used for the synthesis of linked prodrugs, as well as salts and derivatives of the tetrazole group. Reference to ARBs includes reference to pharmaceutically acceptable salts thereof. Valsartan is a diprotic acid. Thus, the angiotensin receptor blocker has a charge of 0.1 or 2 depending on the pH of the solution.

[0035] In the dual-acting compound, particularly the supramolecular complex of the invention, typically the free form of ARB is used in preparation and the cationic components present in the complex are introduced using a base, for example (Kat)OH.

[0036] The dual-acting compound comprises a molecular moiety of a neutral endopeptidase inhibitor. This means that a molecular moiety derived from a neutral endopeptidase inhibitor participates in the structure and dual action of the compound. The neutral endopeptidase inhibitor is part of the compound and is linked to the ARB directly or indirectly via non-covalent bonds. For convenience, in the application, the term "neutral endopeptidase inhibitor" will be used when describing this portion of the compound. The neutral endopeptidase inhibitor used according to the invention is 5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester of formula (II)

[0037] as (2R,4S), i.e. (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester as shown below:

[0038] The compound of formula (II) is a specific inhibitor of NEP and is described in US Pat.

[0039] Patent No. 5,217,996. It may be obtained from commercial sources or may be prepared according to known methods. The compound of formula (II) may be used in the context of the present invention in its free form, as well as in any suitable salt or ester form.

[0040] The compound of formula (II) is a monoprotic acid. Thus, NEPi has a charge of 0 or 1 depending on the pH of the solution.

[0041] In the dual-acting compound, particularly the supramolecular complex of the invention, typically the free form of NEPi is used in the preparation of the cationic components present in the complex introduced using a base, (Kat)OH.

[0042] The dual-acting compound includes non-covalent bonds between ARB and NEPi. It includes a binding moiety that is a pharmaceutically acceptable cation.

[0043] In the invention, the binding moiety is a Na cation. Without wishing to be bound by any particular theory, the acidic moiety of the ARB and NEPi donates a proton to the basic binding moiety such that all three components are then combined to form a molecule. When the bound prodrug is ingested by the subject for treatment, the more acidic nature of the ingestion environment causes the bound prodrug to separate into individual components upon ingestion and absorption and therefore be converted to the active agents to provide the beneficial biological effect for treating the intended diseases.

[0044] The dual-acting compound, in particular the complex according to the invention contains a solvent. The solvent may contribute to the intermolecular structure, for example the supramolecular interactions. In the invention the solvent is water. The water may be present in non-stoichiometric amounts. This means preferably any stoichiometric fraction of the solvent, such as 0.25, 0.5, 0.75, 1.25, 1.5, 1.75, 2.25, 2.5, and 2.75, preferably 2.5, molecules of water, may be present per molecule of active agent. The dual-acting compound, in particular the complex, is in crystalline form, and the solvent may be part of the molecular packing and be trapped in the crystal lattice.

[0045] Thus, in a preferred embodiment of the invention, the dual-acting compound, in particular the supramolecular complex, is described by the molecular formula: [ARB(NEPi)]Nai-3 • xH2O, wherein x is 0 to 3, such as 2.5, where the NEP inhibitor is (2i?,4»S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, and the angiotensin receptor antagonist is valsartan, preferably [ARB(NEPi)]Na3 • xH2O, wherein x is 0 to 3, such as 2.5,

[0046] wherein the NEP inhibitor is (2?,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, and the angiotensin receptor antagonist is valsartan, more preferably

[0047] [(N-valeyl-N-{[2,-(1 / f-tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine)(5-biphenyl4-yl-5-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester]Na3 • x H2O, especially [((5)-N-valeryl-N-{[2,-(1 / f-tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine)((2i?,45)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester]Na3 • x H2O, wherein x is 0 to 3, such as 2.5. In this most preferred example, the complex is designated trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(5)-3'- methyl 2' -(pentanoyl {2'' -(tetrazol-5-ylate)biphenyl-4' -ylmethyl} amino)butyrate] hemipentahydrate.

[0048] A simplified structure of trisodium [3-((15',3i?)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3 '-methyl-2' -(pentanoyl {2'' -(tetrazol-5-ylate)biphenyl-4' -ylmethyl}amino)butyrate] hemipentahydrate used to formally calculate the relative molecular mass is shown below.

[0049] Valsartan comprises two acidic moieties: the carboxylic acid and the tetrazole. In one embodiment of this aspect of the invention, the molecular structure of the dual-acting compound, particularly the complex, of valsartan and a NEPi comprises an interaction between the carboxylic acid and the cation, such as Na, or the solvent, such as water, or a bond between the tetrazole moiety and the cation, such as Na, or the solvent, such as water. In yet another embodiment, the dual-acting compound, particularly the complex, comprises an interaction between the valsartan carboxylic acid moiety, the tetrazole moiety or the NEPi moiety and the cation, such as Na, or the solvent, such as water.

[0050] The combination or dual-acting compound, especially the complex, of the present invention is preferably in solid form. In the solid state it may be in crystalline, partially crystalline, amorphous or polymorphic form, preferably in crystalline form.

[0051] The dual-acting compound, especially the complex, according to the invention is different from a combination of an ARB and a NEPi obtained by only and physically mixing the two active agents. Thus, it may have different properties that make it particularly useful for manufacturing and therapeutic applications. The difference between the dual-acting compound, especially the complex, and the combination can be exemplified by the dual-acting compound (*S)-Δ^-valeryl-Δ^-{[2'-(1 / f-tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine and (2i?,4»S)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester as claimed which is characterized by very distinct spectral peaks and shifts that are not observed in the physical mixture.

[0052] Specifically, such a dual-acting compound is preferably characterized by an X-ray powder diffraction pattern taken with a Scintag XDS2000 powder diffractometer using Cu-Kα radiation (lambda = 1.54056 A) with a Peltier-cooled silicon detector at room temperature (25°C). The scan range was from 1.5 degrees to 40 degrees in 2 theta with a scan rate of 3 degrees / minute. The most important reflections in the X-ray diffraction pattern include the following interplane intervals: The preferred characterization of trisodium [3-((15',3i?)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(5)-3 '-methyl-2'-(pentanoyl {2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate is obtained from the interplane intervals in the obtained X-ray diffraction patterns, whereby, in the following, average values ​​20 in [°] are indicated (error margin ± 0.2)

[0053] 4.5, 5.5, 5.6, 9.9, 12.8, 15.7, 17.0, 17.1, 17.2, 18.3, 18.5, 19.8, 21.5, 21.7, 23.2, 23.3, 24.9, 25.3, 27.4, 27.9, 28.0, 30.2, or with a margin of error of + 0.1:

[0054] 4.45, 5.52, 5.57, 9.94, 12.82, 15.66, 17.01, 17.12, 17.2, 18.32, 18.46, 19.76, 21.53, 21.72, 23.17, 23.27, 24.88, 25.3, 27.4, 27.88, 28.04, 30.2,

[0055] The most intense reflections in the X-ray diffraction pattern show the following interlattice plane intervals: 20 in [°]: ,4.5, 5.6, 12.8, 17.0, 17.2, 19.8, 21.5, 27.4, especially 4.45, 5.57, 17.01, 17.2, 19.76, 21, 27.4.

[0056] A preferred method for checking the above-indicated average values ​​of the interlattice plane intervals and intensities measured experimentally from X-ray diffraction, for a given substance, consists in calculating these intervals and their intensities from detailed single crystal structure determination. The structure determination provides cell constants and atomic positions, which allow the X-ray diffraction diagram to correspond to the solid to be calculated by means of computer-aided calculation methods. The program used is Powder Pattern within the application software Materials Studio (Accelrys).A comparison of these data, namely the interplane spacings and the intensities of the principal lines of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)-propionate-(S)-3'-methyl-2'-(pentanoyl {2''-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)-butyrate] hemipentahydrate, obtained from measurements and from calculating single crystal data, is illustrated in the table below.

[0057] The invention relates to trisodium [3-((1»S',3i2)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3 '-methyl-2' -(pentanoyl {2'' -(tetrazol-5-ylate)biphenyl-4' - ylmethyl}amino)butyrate] hemipentahydrate, a crystalline solid which is characterized by data and parameters obtained from single crystal X-ray analysis and X-ray powder patterns. A detailed discussion of the theory of single crystal X-ray diffraction methods and definition of the evaluated crystal data and parameters can be found in Stout & Jensen, X-Ray Structure Determination; A Practical Guide, Mac Millian Co., New York, NY (1968) chap. 3. Single Crystal X-ray Measurement Data Notes:

[0058] Two data sets on two suitable single crystals were collected at two different temperatures to ensure no phase change upon cooling.

[0059] None of the hydrogen atoms on the water or amine nitrogen atoms were observed in the Fourier maps so these were not included in the refinement. Computer program used to solve the structure SHELXD (Sheldrick, Gottingen)

[0060] In three dimensions, the unit cell is defined by three edge lengths a, b and c, and three interaxial angles a, P and y. In this way, the volume of the unit cell Vc is determined. A differentiated description of these crystal parameters is illustrated in Chapter 3 of Stout & Jensen (see above). The details of trisodium ^-((luS^^-1-biphenyl-ylmethyl-S-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3 '-methyl-2'-(pentanoyl {2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate from single crystal measurements, in particular the atomic coordinates, the isotropic thermal parameters, the coordinates of the hydrogen atoms as well as the corresponding isotropic thermal parameters, show that a monoclinic unit cell exists, where its cell content of twelve formula units of C48H55N60gNa3 • 2.5 H2O occurs as a result of two asymmetric units at double positions.

[0061] The acentric space group P2i determined from the single crystal X-ray structure is a common space group for enantiomorphically pure molecules. In this space group there are two general positions which mean that for twelve formula units in the unit cell there must be 18 sodium ions and 15 water in the asymmetric unit.

[0062] A photographic representation of the unit cell of the supramolecular complex of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)-propionate-(»S)-3'-methyl-2'-(pentanoyl{2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}-amino)butyrate] hemipentahydrate includes two asymmetric units as shown in Fig. 1.

[0063] Based on the single crystal structure solution, the asymmetric unit of the trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)-propionate-(5)-3'-methyl-2'-(pentanoyl{2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}-amino)butyrate] hemipentahydrate supramolecule includes six each of the ARB and NEPi constituents, 18 sodium atoms, and 15 water molecules. Trisodium [3-((1»S',3i2)-1-biphenyl-4-ylmethyl-3 -ethoxycarbonyl-1 -butylcarbamoyl)propionate-(»S)-3' -methyl-2' -(pentanoyl {2" -

[0064] (tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate can be considered as a sodium supramolecular complex, coordinated by oxygen ligands. These oxygens come from twelve carboxylate groups and eighteen carbonyl groups of the constituents

[0065] above, and from 13 of 15 water molecules. The crystal is an infinite 3-dimensional network of these sodium complexes.

[0066] Such a compound can also be characterized by an infrared absorption spectrum obtained using an Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) spectrometer (Nicolet Magna-IR 560) which shows the following significant bands, expressed in reciprocal wavenumbers (cm-1): 2956 (w), 1711 (st), 1637 (st), 1597 (st), 1488 (w), 1459 (m), 1401 (st), 1357 (w), 1295 (m), 1266 (m), 1176 (w), 1085 (m), 1010 (w), 942 (w), 907 (w), 862 (w), 763 (st), 742 (m), 698 (m), 533 (st). Characteristic of the complex are in particular the following peaks 171 l(st), 1637(st), 1597(st) and 1401(st). The margin of error for all absorption bands of ATR-IR is ± 2 cm"1. The intensities of the absorption bands are indicated as follows: (w) = weak; (m) = medium; and (st) = strong intensity.

[0067] Such a compound can also be characterized by a Raman spectrum measured by a dispersive Raman spectrometer with a 785 nm laser excitation source (Kaiser Optical Systems, Inc.) which shows the following significant bands expressed in reciprocal wavenumbers (cm"1): 3061 (m), 2930 (m, broad), 1612 (st), 1523 (m), 1461 (w), 1427 (w), 1287 (st), 1195 (w), 1108 (w), 11053 (w), 1041 (w), 1011 (w), 997 (m), 866 (w), 850 (w), 822 (w), 808 (w), 735 (w), 715 (w), 669 (w), 643 (w), 631 (w), 618 (w), 602 (w), 557 (w), 522 (w), 453 (w), 410 (w), 328 (w).

[0068] The margin of error for all Raman bands is ± 2 cm"1. The intensities of the absorption bands are indicated as follows: (w) = weak; (m) = medium; and (st) = strong intensity.

[0069] Such a compound can also be characterized by specific melting properties measured by differential scanning calorimetry (DSC). Using a Q1000 (TA Instruments) instrument, the melting onset temperature and peak maximum temperature for such a complex were observed at 139°C and 145°C, respectively. The heating rate is 10 K / min.

[0070] The second embodiment of the invention relates to pharmaceutical compositions comprising the dual-acting compound, in particular the complex as described herein and at least one pharmaceutically acceptable additive. The details of the compound and the complex, which include ARB and NEPi, are as described above.

[0071] The pharmaceutical compositions of the invention can be prepared in a manner known per se and are suitable for enteral, such as oral or rectal, and parenteral administration to mammals (warm-blooded animals), including humans, comprising a therapeutically effective amount of the combination or dual-acting compound, especially the complex, alone or in combination with at least one pharmaceutically acceptable carrier, especially suitable for enteral or parenteral application. Typical oral formulations include tablets, capsules, syrups, elixirs and suspensions. Typical injectable formulations include mixtures of dissolved compounds and suspensions.

[0072] Pharmaceutically acceptable additives suitable for use in accordance with the invention include, without limitation, and provided that they are chemically inert so as not to adversely affect the combination or dual-acting compound, particularly the complex of the invention, diluents or fillers, disintegrants, glidants, lubricants, binders, colorants, and combinations thereof. The amount of each additive in a solid dosage formulation will vary within limits known in the literature. Typical pharmaceutically acceptable carriers for use in the formulations described above are exemplified by: sugars, such as lactose, sucrose, mannitol, and sorbitol; starches, such as corn starch, tapioca starch, and potato starch; cellulose and derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and methylcellulose; calcium phosphates, such as dicalcium phosphate and tricalcium phosphate; sodium sulfate; calcium sulfate; polyvinylpyrrolidone; polyvinyl alcohol;stearic acid; alkaline earth metal stearates, such as magnesium stearate and calcium stearate; stearic acid; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; nonionic, cationic, and anionic surfactants; ethylene glycol polymers; β-cyclodextrin; fatty alcohols; and hydrolyzed cereals, as well as other nontoxic compatible fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, flavorings, and the like, which are commonly used in pharmaceutical formulations.;

[0073] Pharmaceutical preparations for enteral or parenteral administration are, for example, in unit dosage forms, such as coated tablets, capsules or suppositories and also ampoules. These are prepared in a manner known per se, for example by using conventional mixing, granulation, coating, dissolution or lyophilization processes. Thus, the pharmaceutical compositions for oral use can be obtained by combining the bound prodrug, combination or dual-acting compound, in particular the complex, with solid excipients, if desired, granulating a mixture which has been obtained, and if required or necessary, processing the mixture or granulate into

[0074] tablets or coated tablet cores after adding suitable excipients.

[0075] The dosage of the active compounds in the combination or dual-acting compound, particularly the complex, depends on a number of factors, such as the route of administration, homeothermic nature, age and / or the individual condition. Reported efficacy in animal disease models ranges from about 0.1 mg / kg / day to about 1000 mg / kg / day given orally, and the reported dosage for human treatment ranges from about 0.1 mg / day to about 2000 mg / day. Preferred ranges are from about 40 mg / day to about 960 mg / day of the bound prodrug, preferably about 80 mg / day to about 640 mg / day. The ARB component is administered at a dose of from about 40 mg / day to about 320 mg / day and the NEPi component is administered at a dose of from about 40 mg / day to about 320 mg / day. More specifically, the dosages of ARB / NEPi include, respectively, 40 mg / 40 mg, 80 mg / 80 mg, 160 mg / 160 mg, 320 mg / 320 mg, 40 mg / 80 mg, 80 mg / 160 mg, 160 mg / 320 mg, 320 mg / 640 mg, 80 mg / 40 mg, 160 mg / 80 mg and 320 mg / 160 mg, respectively.These dosages are "therapeutically effective amounts". Preferred dosages for the bound prodrug, combination or dual-acting compound, particularly the complex of the pharmaceutical composition of the invention, are therapeutically effective doses.

[0076] The pharmaceutical compositions may additionally contain other therapeutic agents, for example, each at an effective therapeutic dose as reported in the literature. Such therapeutic agents include: a) antidiabetic agents such as insulin, insulin derivatives and mimetics; insulin secretagogues such as sulfonylureas, for example Glipizide, glyburide and Amaryl; insulinotropic sulfonylurea receptor ligands such as meglitinides, for example nateglinide and repaglinide; peroxisome proliferator-activated receptor (PPAR) ligands; protein tyrosine phosphatase-1B (PTP-1B) inhibitors such as PTP-112; GSK3 (glycogen synthase kinase-3) inhibitors such as SB-517955, SB-4195052, SB-216763, NN-57-05441 and NN-57-05445; RXR ligands such as GW-0791 and AGN-194204; sodium-dependent glucose cotransporter inhibitors such as T-1095; glycogen phosphorylase A inhibitors such as BAY R3401; biguanides such as metformin; alpha-glucosidase inhibitors such as acarbose;GLP-1 (glucagon-like peptide-1), GLP-1 analogs such as Exendin-4 and GLP-1 mimetics; and DPPIV (dipeptidyl peptidase IV) inhibitors such as LAF237; b) hypolipidemic agents such as 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, for example lovastatin, pitavastatin, simvastatin;

[0077] pravastatin, cerivastatin, mevastatin, velostatin, fluvastatin, dalvastatin, atorvastatin, rosuvastatin and rivastatin; squalene synthase inhibitors; FXR (farnesoid X receptor) and LXR (liver X receptor) ligands; cholestyramine; fibrates; nicotinic acid and aspirin; c) anti-obesity drugs such as orlistat; and

[0078] d) anti-hypertensive agents, for example loop diuretics such as ethacrynic acid,

[0079] furosemide and torsemide; angiotensin-converting enzyme (ACE) inhibitors such as

[0080] benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril and trandolapril; inhibitors of the Na-K-ATPase membrane pump such as digoxin; ACE / NEP inhibitors such as omapatrilat, sampatrilat and fasidotril; β-adrenergic receptor blockers such as acemenolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, sotalol and timolol; inotropic agents such as digoxin, domenamine and milrinone; calcium channel blockers such as amlodipine, bepridil, diltiazem, felodipine, nicardipine, nimodipine, nifedipine, neroldipine and verapamil; aldosterone receptor antagonists; and aldosterone synthase inhibitors. Most preferred combination partners are diuretics, such as hydrochlorothiazide and / or calcium channel blockers, such as amlodipine or a salt thereof.

[0081] Other specific anti-diabetic compounds are described by Patel Mona in Expert Opin Investig Drugs, 2003, 12(4), 623-633, in Fig. 1 to 7, which are incorporated by reference herein. A compound of the invention may be administered either simultaneously, before or after the other active ingredient, either separately by the same or different route of administration or together in the same pharmaceutical formulation.

[0082] The structure of the therapeutic agents identified by code number, generic or trade name, may be taken from the current edition of the standard compendium "The Merck Index" or from databases, such as Patents International (e.g. IMS World Publications). The corresponding contents thereof are incorporated herein by reference.

[0083] Accordingly, the present invention provides pharmaceutical compositions in addition to a therapeutically effective amount of other therapeutic agents, preferably selected from anti-diabetic agents, hypolipidemic agents, anti-obesity agents or anti-hypertensive agents, most preferably from anti-diabetic agents, anti-hypertensive agents or hypolipidemic agents as described above.

[0084] The skilled person is fully capable of selecting a relevant test model to test the efficacy of a combination according to the invention in relation to the aforementioned or the hereinafter indicated therapeutic indications.

[0085] Representative studies have been performed with trisodium [3-((15',3i?)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(5)-3 '-methyl-2'-(pentanoyl {2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate, for example, using the following methodology: The antihypertensive and neutral endopeptidase 24.11 (NEP) inhibitor activities of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(pentanoyl {2''-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate are determined in conscious rats. Blood pressure lowering effect evaluated in double transgenic rats (dTGRr) that overexpress both human renin and its substrate, human angiotensinogen (Bohlender, et al, High human renin hypertension in transgenic rats. Hypertension; 29(1 Pt 2):428-34,1997). As a consequence, these animals exhibit angiotensin II-dependent hypertension.The NEP inhibitory effect of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)-propionate-(S)-3'-methyl-2'-(pentanoyl {2''-(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)-butyrate] hemipentahydrate is determined in conscious Sprague-Dawley rats infused with exogenous atrial natriuretic peptide (ANP). Potentiation of plasma ANP levels is used as an index of NEP inhibition in vivo. In both models, trisodium [3-(( IS, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(5)-3'-methyl-2'-(pentanoyl{2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate was administered orally as a powder in gelatin minicapsules. The results are summarized below.

[0086] • Trisodium [3-((1»S',3i2)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl-carbamoyl)propionate-(5)-3'-methyl-2'-(pentanoyl{2"-(tetrazol-5-ylat)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate exhibits a dose-dependent and long-acting antihypertensive effect after oral administration to conscious dTGRs, a rat model of fulminant hypertension.

[0087] • Oral administration of trisodium [3-((15',3i?)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1 -butylcarbamoyl)propionate-(S)-3' -methyl-2' -(pentanoyl {2" -

[0088] (tetrazol-5-ylat)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate rapidly and dose-dependently inhibits NEP with a long duration of action, which is reflected by

[0089] its potentiation of plasma ANP immunoreactivity (ANPir) in conscious Sprague-Dawley rats infused with exogenous ANP. Antihypertensive effect in vivo

[0090] The dTGRs are instrumented with radiotelemetry transmitters to continuously measure arterial blood pressure and heart rate. Animals are randomly assigned to vehicle (empty capsule) or treatment (at 2, 6, 20, or 60 mg / kg, po) groups. Baseline 24-hour mean arterial pressure (MAP) is approximately 170-180 mm Hg in all groups. Trisodium [3-(( IS, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(5)-3'-methyl-2'-(pentanoyl {2''-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate dose-dependently reduces MAP. The values ​​obtained from the treatment groups are dose-dependent, and the results from the three highest doses are significantly different from the vehicle controls. Inhibition of NEP in vivo

[0091] The extent and duration of trisodium [3-((15',3i?)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(5)-3'-methyl-2'-(pentanoyl {2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate for NEP inhibition in vivo was determined using methodologies previously described (Trapani, et al, CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol; 44(Suppl 1):S211-5, 2004). Rat ANP(1-28) was infused intravenously at a rate of 450 ng / kg / min into continuous, chronically cannulated, male rats. Sprague-Dawley rats. After one hour of infusion, rats were randomly assigned to one of six groups: untreated control, vehicle (empty capsule) control, or one of four doses of drug (2, 6, 20, or 60 mg / kg, po). ANP infusion continued for an additional eight hours.Blood samples are collected for measurement of plasma ANPir with a commercial enzyme immunoassay kit at -60 min (i.e., before initiation of ANP infusion), -30 min (after 30 min of ANP infusion), 0 min ("baseline"; after 60 min of ANP infusion but before dosing with drug or its vehicle), and at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, and 8 hours after dosing.

[0092] Before ANP infusion, ANPir is low (0.9-1.4 ng / ml) and similar in all six groups. ANP infusion rapidly (within 30 min) raises ANPir to ~10 ng / ml. This ANPir level is sustained throughout the experiment in untreated and vehicle control groups. In contrast, trisodium [3-((1»S',3i2)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3 '-methyl-2' -(pentanoyl {2'' -(tetrazol-5-ylat)biphenyl-4' - ylmethyl}amino)butyrate] hemipentahydrate rapidly (within 15 min) and dose-dependently increases ANPir. In summary, orally administered LCZ696 rapidly and dose-dependently inhibits NEP with a long duration of action as reflected by the potentiation of plasma ANPir.

[0093] The available results indicate an unexpected therapeutic effect of a compound according to the invention.

[0094] The dual-acting compound of the invention can be prepared by a process comprising

[0095] (i) dissolving the angiotensin receptor antagonist (S)-N-valeryl-N-{[2'-(1-tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine) and the neutral endopeptidase inhibitor (NEPi) (2',4'S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in a suitable solvent; (ii) dissolving a basic compound of Na in a suitable solvent; (iii) combining the solutions obtained in steps (i) and (ii); (iv) precipitating the solid and drying the same to obtain the dual-acting compound; or alternatively

[0096] obtain the dual-acting compound by replacing the solvents used in steps (i) and (ii) by

[0097] (iva) evaporating the resulting solution to dryness;

[0098] (va) redissolving the solid in a suitable solvent;

[0099] (via) precipitating the solid and drying the same to give the dual-acting compound.

[0100] Details regarding the complex, which includes ARB, NEPi and the cation, are described above with respect to the first embodiment of the invention.

[0101] Preferably, in step (i), ARB and NEPi are added in an equivalent molar amount. Both ARB and NEPi are preferably used in the free form. The solvent used in step (i) may be any solvent that allows dissolution of both ARB and NEPi. Preferred solvents include water, methanol, ethanol, 2-propanol, acetone, ethyl acetate, isopropyl acetate, methyl-t-butyl ether, acetonitrile, toluene, DMF, NMF and methylene chloride and mixtures of such solvents, such as ethanol-water, methanol-water, 2-propanol-water, acetonitrile-water, acetone-water, 2-propanol-toluene, ethyl acetate-heptane, isopropyl acetate-acetone, methyl-t-butyl ether-heptane, methyl-t-butyl ether-ethanol, ethanol-heptane, acetone-ethyl acetate, acetetone-cyclohexane, toluene-heptane, more preferably acetone.

[0102] Preferably, in step (ii) the basic compound of Na is a compound capable of forming a salt with the acidic functionalities of ARB and NEPi, such as NaOH. The basic compound is used in an amount of at least 3 equivalents relative to either ARB or NEPi, preferably it is used in a stoichiometric amount to give the dual-acting compound, in particular the complex with three cations. The solvent used in step (ii) can be any solvent or mixture of solvents that allows the dissolution of the basic compound of Na. Preferred solvents include water, methanol, ethanol, 2-propanol, acetone, ethyl acetate, isopropyl acetate, methyl-t-butyl ether, acetonitrile, toluene and methylene chloride and mixtures of such solvents, more preferably water.

[0103] In step (iii), the solutions obtained in steps (i) and (ii) are combined. This can be done by adding the solution obtained in step (i) to the solution obtained in step (ii) or vice versa, preferably the solution obtained in step (ii) to the solution obtained in step (i).

[0104] According to the first alternative, when they are combined and preferably mixed, the dual-acting compound, in particular the complex, precipitates in step (iv). This mixing and precipitation is typically carried out by stirring the solutions for a suitable period of time such as 20 minutes to 6 hours, preferably 30 minutes to 3 hours, more preferably 2 hours, at room temperature. It is advantageous to seed the dual-acting compound. This method facilitates precipitation.

[0105] In step (iv), according to this first alternative, a co-solvent is typically added. The co-solvent used is a solvent in which ARB and NEPi in the complexed form exhibit a low solubility which allows the compound to precipitate. Distillation, either continuously or stepwise, with replacement of this co-solvent results in a mixture primarily of co-solvent. Preferred solvents include ethanol, 2-propanol, acetone, ethyl acetate, isopropyl acetate, methyl-?-butyl ether, acetonitrile, toluene and methylene chloride and mixtures of such solvents, more preferably isopropyl acetate. Preferably, a minimum amount of solvent is used to facilitate precipitation. The solid is collected, for example by filtration, and stirred to obtain the dual-acting compound, in particular the complex, of the invention. Drying steps may be carried out at room temperature or elevated temperature, such as 30 to 60°C, preferably 30 to 40°C.Reduced pressure may be used to facilitate removal of the solvent, preferably drying is carried out at ambient pressure or reduced pressure of, for example, 10 to 30 bar, such as 20 bar.

[0106] According to a second alternative, when the mixture is combined and preferably mixed, the dual-acting compound, in particular the complex of the mixture, preferably a clear solution is mixed. This mixing is typically carried out by stirring the solutions for a suitable period of time such as 20 minutes to 6 hours, preferably 30 minutes to 3 hours, more preferably 1 hour, at room temperature. If necessary, the temperature can be raised to obtain a clear solution.

[0107] The obtained mixture is then further treated by solvent exchange to obtain the dual-acting compound, in particular the complex.

[0108] In step (iva) according to this second alternative, the solution is preferably evaporated to dryness at elevated temperatures such as > room temperature to 50°C, more preferably 30 to 40°C.

[0109] Preferably, in step (va) the solvent or solvent mixture used is a solvent in which the ARB and NEPi in complexed form exhibit a low solubility which enables the dual-acting compound, in particular the complex, to precipitate. Preferred solvents include those mentioned above in step (i), such as water, ethanol, 2-propanol, acetone ethyl acetate, isopropyl acetate, methyl-t-butyl ether, acetonitrile, toluene and methylene chloride and mixtures of such solvents, more preferably isopropyl acetate. Preferably, a minimum amount of solvent or solvent mixture is used to facilitate precipitation.

[0110] In step (via), precipitation may take place at room temperature. It may be effected by allowing the mixture to stand or by stirring the mixture, preferably by stirring. It is preferably effected by stirring and / or sonication. After precipitation, the solid is collected, for example by filtration, and dried to give the compound of the invention. The drying step may be carried out at room temperature or elevated temperature such as 30 to 60°C, preferably room temperature. Reduced pressure may be used to facilitate removal of the solvent, preferably drying is carried out at ambient pressure.

[0111] In a third aspect, the present invention relates to the dual-acting compound according to claim 1 for the preparation of a medicament for use in a method of treating or preventing a disease or condition, such as hypertension, heart failure (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial fibrillation, harmful vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria in primary renal disease and also renal vascular hypertension, diabetic retinopathy, other vascular disorders,such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke.,

[0112] The dual-acting compound, especially the complex, according to the first embodiment, can be administered alone or in the form of a pharmaceutical composition according to the second embodiment. Information regarding dosage, i.e. the therapeutically effective amount, etc., is the same regardless of how the dual-acting compound, especially the complex is administered.

[0113] The dual-acting compound, especially the complex, is advantageous over a combination of ARBs or neutral endopeptidase inhibitors alone or other ARB / NEPi combinations, with respect to their use as first-line treatment, ease of formulation and ease of manufacture.

[0114] Specific embodiments of the invention will now be demonstrated by reference to the following examples. It is to be understood that these examples are described only to illustrate the invention and are not to be taken as limiting the scope of the invention in any way. Example 1

[0115] Preparation of [valsartan ((2 / ?,4S)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester]Na3 • 2.5 H2O

[0116] The dual-acting compound of valsartan and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester is prepared by dissolving 0.42 g of (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester free acid (~95% purity) and 0.4 lg of valsartan free acid in 40 ml of acetone. Separately, 0.11 lg of NaOH is dissolved in 7 ml of H2O. The two solutions are combined and stirred at room temperature for 1 hour and a clear solution is obtained. The solution is evaporated at 35°C to give a glassy solid. The glassy solid residue is then added to 40 ml of acetone and the resulting mixture is stirred and sonicated until precipitation occurs (~5 minutes). The precipitate is filtered and the solid is dried at room temperature in the open air for 2 days until a constant mass of the crystalline solid is obtained.

[0117] Characterization by various methods confirms the presence of both valsartan and (2?,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester and complex formation as opposed to a simple physical mixture. Significant spectral peaks for the complex are observed, for example, in XRPD, IR and Raman spectroscopy that are not present in the physical mixture. See below for details regarding characterization. Example 2

[0118] Alternative preparation of [valsartan ((2 / ?,4S)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester]Na3 • 2.5 H2O

[0119] The dual-acting compound of valsartan and (2i?,4»S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester is prepared by dissolving 22.96 mmol of (2i?,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester free acid (-95% purity) and valsartan (10.00 g; 22.96 mmol) in acetone (300 ml). The suspension is stirred at room temperature for 15 minutes to obtain a clear solution. A solution of NaOH (2.76 g; 68.90 mmol) in water (8 ml) is then added to the solution over 10 minutes. Solids begin to precipitate within 10 minutes. Alternatively, precipitation can be induced by seeding. The suspension is stirred at 20-25°C for 2 hours. This suspension is concentrated at 15-30°C under reduced pressure (180-250 mbar) to a batch volume of -150 ml. Isopropyl acetate (150 ml) is then added to the batch and the suspension is concentrated again at 15-30°C under reduced pressure (180-250 mbar) to a batch volume of -150 ml.This operation (addition of 150 ml of isopropyl acetate to the batch and concentration) is repeated once more. The suspension is stirred at 20-25°C for 1 hour. The solids are collected by filtration under nitrogen over a Büchner funnel, washed with isopropyl acetate (20 ml) and dried at 35°C under reduced pressure (20 mbar) to give the compound. Characterization revealed the same product as in Example 1. Example 3

[0120] Alternative preparation of [valsartan ((2P,4S)-5-biphenyl4-yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester]Na3 • 2.5 H2O using seeding

[0121] To a reactor is added 2.00 kg (2.323 mmol) of AHU377 calcium salt and 20 L of isopropyl acetate.

[0122] The suspension is stirred at 23 ± 3°C, and 4.56 L of iVHCl is added. The mixture is stirred at 23 ± 3°C for 15 minutes to obtain a clear two-phase solution. The organic layer is separated and washed with 3 x 4.00 L of water. The organic layer is concentrated at 30-100 mbar and 22 ± 5°C to -3.5 L (3.47 kg) of AHU377 free acid isopropyl acetate solution as a colorless solution.

[0123] To the above reactor containing -3.5 L (347 kg) of AHU377 free acid isopropyl acetate solution is added 1.984 kg (4556 mmol) of Valsartan and 40 L of acetone. The reaction mixture is stirred at 23 ± 3°C to give a clear solution which is filtered into a reactor. To the reaction mixture is added a solution of 547.6 g (13690 mmol) of NaOH in 1.0 L of water at 23 ± 3°C (which is pre-cooled to 20 ± 5°C and filtered in-line) over 15-30 minutes while maintaining the internal temperature at 20-28°C (slightly exothermic). The flask is rinsed with 190 mL of water and added to the reaction mixture. The reaction mixture is stirred at 23 ± 3°C for 15 minutes and a slurry of 4.0 g [valsartan ((2i?,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester]Na3 «2.5 H20 seed crystals in 50 ml isopropyl acetate is added. The mixture is stirred at 23 ± 3°C for 2 hours to obtain a suspension.The suspension is heated to an internal temperature of 40 ± 3°C over 20 minutes and 20 l of isopropyl acetate are added over a period of 20 minutes while maintaining the internal temperature at 40 ± 3°C. The suspension is stirred at this temperature for a further 30 minutes. The mixture is concentrated at an internal temperature of 35 ± 5°C (Tj 45 ± 5°C) under reduced pressure (200-350 mbar) to -35 l of a white slurry (solvent collected: -25 L). Then 30 l of isopropyl acetate are added to the mixture which is concentrated at an internal temperature of 35 ± 5°C (Tj 45 ± 5°C) under reduced pressure (100-250 mbar) to -30 l of a white slurry (solvent collected: -40 l). Again 40 l of isopropyl acetate are added and the mixture is concentrated at an internal temperature of 35 ± 5°C (Tj 45 ± 5°C) under reduced pressure (100-200 mbar) to -30 l of a white slurry (solvent collected: -30 l).The reaction mixture is cooled to 23 ± 3°C over -20 minutes and stirred at this temperature for a further 3 hours. The solid is collected by filtration under nitrogen over a polypropylene pad on a Büchner funnel. The solid is washed with 2X5 l of isopropyl acetate and dried at 35°C under reduced pressure (20 mbar) to isopropyl acetate content < 0.5% to give the above product as a white solid.

[0124] Characterization revealed the same product as in Example 1. X-ray powder diffraction

[0125] Calculation of interlattice plane intervals from the X-ray powder pattern taken with a Scintag XDS2000 powder diffractometer for the most important lines for the sample gave the following results: di [ Å ] : 21.2(s), 17.0(w), 7.1(s), 5.2(w), 4.7(w), 4.6(w), 4.2(w), 3.5(w), 3.3(w)

[0126] The error margin for all interlattice plane intervals is ± 0.1 Å. The intensities of the peaks are indicated as follows: (w) = weak; (m) = medium; and (st) = strong.

[0127] Average values ​​2 0 in [°] are indicated (error margin ±0.2)

[0128] 4.5, 5.5, 5.6, 9.9, 12.8, 15.7, 17.0, 17.1, 17.2, 18.3, 18.5, 19.8, 21.5, 21.7, 23.2, 23.3, 24.9, 25.3, 27.4, 27.9, 28.0, 30.2. Elemental analysis

[0129] Elemental analysis gives the following measured values ​​for the elements present in the sample. The findings of the elemental analysis, within the margins of error, correspond to the overall formula (C48H55N608Na3)«2.5H20

[0130] Infrared spectroscopy

[0131] The infrared absorption spectrum of the sample obtained using Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) spectrometer (Nicolet Magna-IR 560) shows the following significant bands, expressed in reciprocal wavenumbers (cm"1): 2956 (w), 1711 (st), 1637 (st), 1597 (st), 1488 (w), 1459 (m), 1401 (st), 1357 (w), 1295 (m), 1266 (m), 1176 (w), 1085 (m), 1010 (w), 942 (w), 907 (w), 862 (w), 763 (st), 742

[0132] (m), 698 (m), 533 (st)- The margin of error for all absorption bands of ATR-IR is ± 2 cm"1.

[0133] The intensities of the absorption bands are indicated as follows: (w) = weak; (m) = medium; and (st) = strong intensity. Raman spectroscopy

[0134] Raman spectrum of the sample measured by dispersive Raman spectrometer with 785 nm laser excitation source (Kaerer Optical Systems, Inc,) shows the following significant bands expressed in reciprocal wavenumbers (cm"1): 3061 (m), 2930 (m, broad), 1612 (st), 1523 (m), 1461 (w), 1427 (w), 1287 (st), 1195 (w), 1108 (w), 11053 (w), 1041 (w), 1011 (w), 997 (m), 866 (w), 850 (w), 822 (w), 808 (w), 735 (w), 715 (w), 669 (w), 643 (w), 631 (w), 618 (w), 602 (w), 557 (w), 522 (w), 453 (w), 410 (w), 328 (w). The margin of error for all Raman bands is ± 2 cm"1.

[0135] The intensities of the absorption bands are indicated as follows: (w) = weak; (m) = medium; and (st) = strong intensity. High-resolution CP-MAS 13C NMR Spectroscopy

[0136] The samples are examined by high-resolution CP-MAS S (Cross Polarization Magic Angle Spinning) 13C NMR spectroscopy using a Bruker-BioSpin AVANCE 500 NMR spectrometer equipped with a 300 Watt high-power 1H, two 500 Watt high-power X-amplifiers, necessary high-power preamplifiers, a "MAS" controller and a 4 mm BioSolids high-resolution Bruker probe.

[0137] Each sample is packed into a 4mm ZrO2 rotor. Critical experimental parameters are 3 msec 13C contact time, 12 KHz spin rate at magnetic angle, a "stepped" contact time, using a "SPINAL64" JH decoupling scheme, a recycle delay of 10 seconds, and 1024 scans at 293 degrees K. Chemical shifts are referenced with respect to an external cyclin carbonyl at 176.04 ppm. High-resolution CP-MAS 13C NMR shows the following significant peaks (ppm):

[0138] 179.0, 177.9 177.0, 176.7, 162.0, 141.0, 137.2, 129.6, 129.1, 126.7, 125.3, 64.0, 61.5, 60.4, 50.2, 46.4, 40.6, 38.6, 33.5, 32.4, 29.8, 28.7, 22.3, 20.2, 19.1, 17.8, 16.8, 13.1, 12.1,11.1.

[0139] A physical mixture of individual Na salts of Valsartan and (2?,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester revealed a simple inert mixture of the two salts. However, the sample of the complex prepared in Example 1 exhibited distinct spectral features compared to a 1:1 mixture of the sodium salts. DSC and TGA

[0140] As measured by differential scanning calorimetry (DSC) using Q1000 (TA Instruments) instrument, the melting onset temperature and peak maximum temperature of the sample were observed at 139°C and 145°C, respectively.

[0141] As shown by DSC and thermogravimetric analysis (TGA), upon heating, water of hydration was released in two stages: the first stage took place below 100°C and the second stage above 120°C.

[0142] Both the DSC and TGA instruments were operated at a heating rate of 10 K / min.

[0143] While the invention has been described above with reference to specific embodiments thereof, it will be apparent that many changes, modifications and variations can be made without departing from the inventive concept described herein. Accordingly, it is intended to embrace all such changes, modifications and variations that fall within the spirit and scope of the appended claims.

Claims

1. Compound, characterized in that it includes the NEP inhibitor (2i?,4*S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, and the angiotensin receptor antagonist valsartan, and has the formula [((5)-JV-valeryl-JV-{[2'-(1 / / -tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine) ((2i?,45 )-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester)] Nai-3 • x H 2 O, where x is 0 to 3.

2. Compound according to claim 1, characterized in that it has the formula [(((S)-^-valeryl-A^-{[2,-(lif-tetrazol-5-yl)-biphenyl-4-yl]-methyl }-valine) (( 2R , 4S )-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester)]Na3 • x H2O, where x is 0 to 3.

3. Compound according to claim 2, characterized in that it is in crystalline or amorphous form.

4. Compound according to claim 2 or 3, characterized in that x is 2.

5.

5. Compound according to claim 4, characterized in that it is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl- 2'-(pentanoyl {2''-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate]hemipentahydrate.

6. Use of the compound according to any one of claims 1 to 5 for the manufacture of a medicament for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure (acute and chronic), congestive heart failure, left ventricular dysfunction , hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial fibrillation, deleterious vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria in primary renal disease, renal vascular hypertension, diabetic retinopathy, migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction , glaucoma and stroke.

7. Use according to claim 6, where the condition or disease is heart failure (acute and chronic).

8. Use according to claim 6, where the condition or disease is hypertension.